Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRPK2 | P78362 | 1/20 | 0.38 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.37 |
| ▸ | DBH | P09172 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763191 | 0.91 | KCNA3 (0.41) | SRPK2SRPK1P2RX7KCNA3DBH | |
| SCHEMBL1762715 | 0.87 | DDR1 (0.37) | SRPK2SRPK1P2RX7KDRFLT1 | |
| SCHEMBL1762851 | 0.81 | HDAC3 (0.41) | ADORA2A | |
| SCHEMBL1762774 | 0.81 | PKM (0.43) | — | |
| SCHEMBL1762662 | 0.80 | F2R (0.40) | KDRFLT1 | |
| SCHEMBL1762595 | 0.79 | TP53 (0.41) | KDRFLT1 | |
| SCHEMBL1762705 | 0.79 | LMNA (0.42) | DBHADORA2AADORA1 | |
| SCHEMBL1762620 | 0.79 | CYP11B1 (0.40) | KDRFLT1 | |
| SCHEMBL1762935 | 0.78 | HDAC8 (0.47) | — | |
| SCHEMBL1762562 | 0.78 | EPHX2 (0.43) | P2RX7KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633193-B2 | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| US-20110118273-A1 | PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-05-19 | — | — | US | disclosed |
| US-7906528-B2 | Such as 5-(2,6-diethyl-phenyl)-1H-pyrrolo[2,3-C]pyridine, which binds C5a receptors with high affinity; for treatment of inflammatory, cardiovascular, and immune system disorders; kits | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-15 | — | — | US | disclosed |
| US-20080267887-A1 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds | NEUROGEN CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118273-A1 | PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS | C5AR1, C5AR2, C3AR1 | SRPK2 2735/4885SRPK1 3007/4885P2RX7 9/4885 |
| US-20080267887-A1 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds | C5AR1, C5AR2, C3AR1 | SRPK2 2735/4885SRPK1 3007/4885P2RX7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.